» Articles » PMID: 22911011

Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: a Systematic Review and Meta-analysis

Overview
Journal PLoS Med
Specialty General Medicine
Date 2012 Aug 23
PMID 22911011
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.

Methods And Findings: PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count. Eleven studies met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).

Conclusions: Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.

Review Registration: International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.

Citing Articles

Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.

Yue W, Zhai P, Mao J, Ma J, Ren W, Jiang T BMJ Public Health. 2025; 2(2):e001042.

PMID: 40018595 PMC: 11816706. DOI: 10.1136/bmjph-2024-001042.


Pulmonary Tuberculosis-Associated Morbidity in Africa: A Systematic Review.

Okeke C, Ibe C, Nduji O, Ndulue C, Ngige O, Amuchie C Cureus. 2025; 17(1):e77569.

PMID: 39958055 PMC: 11830121. DOI: 10.7759/cureus.77569.


Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review.

Chihota V, Gombe M, Gupta A, Salazar-Austin N, Ryckman T, Hoffmann C Drugs. 2024; 85(2):127-147.

PMID: 39733063 PMC: 11802714. DOI: 10.1007/s40265-024-02131-3.


HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015.

Atkinson A, Kraus D, Banholzer N, Miro J, Reiss P, Kirk O PLoS One. 2024; 19(10):e0312035.

PMID: 39453919 PMC: 11508122. DOI: 10.1371/journal.pone.0312035.


Factors associated with uptake of isoniazid preventive therapy among children living with HIV in Mwanza region, Tanzania: a cross-sectional study.

Tuwa A, Okia D, Nantale R, Jaka H, Alunyo J, Mukunya D BMC Public Health. 2024; 24(1):2221.

PMID: 39148019 PMC: 11325747. DOI: 10.1186/s12889-024-19705-1.


References
1.
Das M, Chu P, Santos G, Scheer S, Vittinghoff E, McFarland W . Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010; 5(6):e11068. PMC: 2883572. DOI: 10.1371/journal.pone.0011068. View

2.
Lawn S, Kranzer K, Edwards D, McNally M, Bekker L, Wood R . Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010; 24(9):1323-8. PMC: 3772277. DOI: 10.1097/QAD.0b013e3283390dd1. View

3.
Anglemyer A, Rutherford G, Egger M, Siegfried N . Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2011; (5):CD009153. DOI: 10.1002/14651858.CD009153. View

4.
Gilks C, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y . The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368(9534):505-10. DOI: 10.1016/S0140-6736(06)69158-7. View

5.
Dye C, Lonnroth K, Jaramillo E, Williams B, Raviglione M . Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ. 2009; 87(9):683-91. PMC: 2739916. DOI: 10.2471/blt.08.058453. View